Freeline Therapeutics Holdings Management
Management criteria checks 2/4
Freeline Therapeutics Holdings' CEO is Michael Parini, appointed in Aug 2021, has a tenure of 2.5 years. total yearly compensation is $2.16M, comprised of 27.4% salary and 72.6% bonuses, including company stock and options. directly owns 1.1% of the company’s shares, worth $310.01K. The average tenure of the management team and the board of directors is 2.1 years and 4.3 years respectively.
Key information
Michael Parini
Chief executive officer
US$2.2m
Total compensation
| CEO salary percentage | 27.4% |
| CEO tenure | 2.5yrs |
| CEO ownership | 1.1% |
| Management average tenure | 2.1yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
Calculating The Intrinsic Value Of Freeline Therapeutics Holdings plc (NASDAQ:FRLN)
Jul 13
Here's Why Freeline Therapeutics Holdings (NASDAQ:FRLN) Must Use Its Cash Wisely
Apr 11Here's Why Freeline Therapeutics Holdings (NASDAQ:FRLN) Must Use Its Cash Wisely
Dec 20We're Keeping An Eye On Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Rate
Aug 30Freeline gains as NEJM publishes long-term data for hemophilia therapy
Jul 21Is Freeline Therapeutics Holdings (NASDAQ:FRLN) In A Good Position To Invest In Growth?
May 05Will Freeline Therapeutics Holdings (NASDAQ:FRLN) Spend Its Cash Wisely?
Jan 13Companies Like Freeline Therapeutics Holdings (NASDAQ:FRLN) Could Be Quite Risky
Sep 30Here's Why We're Watching Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Situation
Jun 03What Kind Of Shareholders Hold The Majority In Freeline Therapeutics Holdings plc's (NASDAQ:FRLN) Shares?
Feb 18
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2023 | n/a | n/a | -US$50m |
| Jun 30 2023 | n/a | n/a | -US$53m |
| Mar 31 2023 | n/a | n/a | -US$61m |
| Dec 31 2022 | US$2m | US$591k | -US$89m |
| Sep 30 2022 | n/a | n/a | -US$101m |
| Jun 30 2022 | n/a | n/a | -US$117m |
| Mar 31 2022 | n/a | n/a | -US$132m |
| Dec 31 2021 | US$1m | US$419k | -US$140m |
Compensation vs Market: Michael's total compensation ($USD2.16M) is above average for companies of similar size in the US market ($USD671.51K).
Compensation vs Earnings: Michael's compensation has increased whilst the company is unprofitable.
CEO
Michael Parini (48 yo)
2.5yrs
Tenure
US$2,160,000
Compensation
Mr. Michael J. Parini, JD., serves as Chief Executive Officer & Executive Director at Freeline Therapeutics Limited since August 16, 2021. He had been President and Chief Operating Officer at Freeline Ther...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 2.5yrs | US$2.16m | 1.1% $ 310.0k | |
| CFO & Director | 1.8yrs | no data | no data | |
| Chief Scientific Officer | 1.9yrs | no data | no data | |
| Chief People Officer | 1.6yrs | no data | no data | |
| Chief Technical Operations Officer | 2.6yrs | no data | no data | |
| Chief Medical Officer | 2.3yrs | no data | no data | |
| Senior Vice President of Corporate Communications & Investor Relations | no data | no data | no data | |
| Interim Head of Finance | no data | no data | no data |
2.1yrs
Average Tenure
52yo
Average Age
Experienced Management: FRLN's management team is considered experienced (2.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 2.5yrs | US$2.16m | 1.1% $ 310.0k | |
| CFO & Director | less than a year | no data | no data | |
| Independent Non-Executive Director | 4.3yrs | US$172.00k | no data | |
| Independent Non Executive Director | 2.9yrs | US$93.00k | no data | |
| Independent Chairman | 8.2yrs | US$93.00k | no data | |
| Independent Non-Executive Director | 4.5yrs | US$166.00k | no data | |
| Independent Non-Executive Director | 5.3yrs | US$154.00k | no data |
4.3yrs
Average Tenure
59yo
Average Age
Experienced Board: FRLN's board of directors are considered experienced (4.3 years average tenure).